The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor.
No takes yet. Share an insight, caveat, or question.
Shirley Lehnert (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: